The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma

Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eko A. Pangarsa, Ridho M. Naibaho, Vina Yunarvika, Budi Setiawan, Damai Santosa, Catharina Suharti
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/6fcc0b7d3d9f405d84deba51ded5dacc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6fcc0b7d3d9f405d84deba51ded5dacc
record_format	dspace
spelling	oai:doaj.org-article:6fcc0b7d3d9f405d84deba51ded5dacc2021-11-15T01:20:08ZThe Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma2090-657910.1155/2021/9632427https://doaj.org/article/6fcc0b7d3d9f405d84deba51ded5dacc2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/9632427https://doaj.org/toc/2090-6579Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin’s lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR-ESHAP) chemotherapy. The ASCT went well without significant complications. This case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript.Eko A. PangarsaRidho M. NaibahoVina YunarvikaBudi SetiawanDamai SantosaCatharina SuhartiHindawi LimitedarticleDiseases of the blood and blood-forming organsRC633-647.5ENCase Reports in Hematology, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Eko A. Pangarsa Ridho M. Naibaho Vina Yunarvika Budi Setiawan Damai Santosa Catharina Suharti The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
description	Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin’s lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR-ESHAP) chemotherapy. The ASCT went well without significant complications. This case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript.
format	article
author	Eko A. Pangarsa Ridho M. Naibaho Vina Yunarvika Budi Setiawan Damai Santosa Catharina Suharti
author_facet	Eko A. Pangarsa Ridho M. Naibaho Vina Yunarvika Budi Setiawan Damai Santosa Catharina Suharti
author_sort	Eko A. Pangarsa
title	The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
title_short	The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
title_full	The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
title_fullStr	The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
title_full_unstemmed	The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
title_sort	use of etoposide, ara-cytarabine, and melphalan (eam) conditioning chemotherapy in autologous stem cell transplantation (asct) for a patient with relapsed hodgkin’s lymphoma
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/6fcc0b7d3d9f405d84deba51ded5dacc
work_keys_str_mv	AT ekoapangarsa theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT ridhomnaibaho theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT vinayunarvika theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT budisetiawan theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT damaisantosa theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT catharinasuharti theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT ekoapangarsa useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT ridhomnaibaho useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT vinayunarvika useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT budisetiawan useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT damaisantosa useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT catharinasuharti useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma
_version_	1718428928330170368

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma

Ejemplares similares